We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+15.07%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.65B
AUM Growth
+$134M
(+8.8%)
Cap. Flow
+$10.7M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
41
New
8
Increased
10
Reduced
10
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$65.6M |
| 2 |
ScottsMiracle-Gro
SMG
|
+$32.7M |
| 3 |
MSGN
MSG Networks Inc.
MSGN
|
+$31.7M |
| 4 |
Bank of America
BAC
|
+$29.6M |
| 5 |
Heron Therapeutics
HRTX
|
+$29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$60M |
| 2 |
DaVita
DVA
|
+$52.3M |
| 3 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$37.8M |
| 4 |
GoDaddy
GDDY
|
+$30.5M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$26.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.41% |
| 2 | Consumer Discretionary | 10.09% |
| 3 | Technology | 8.81% |
| 4 | Communication Services | 8.2% |
| 5 | Financials | 5.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Labcorp
LH
$25.5B
| $99.4M | 6.03% |
715,420
-21,581
| -3% | -$3.17M |
|
2
Atara Biotherapeutics
ATRA
$74.4M
| $99M | 6.01% |
101,569
-2,375
| -2% | -$2.16M |
|
|
3
GoDaddy
GDDY
$10.5B
| $91.9M | 5.58% |
1,496,992
-539,597
| -26% | -$30.5M |
|
|
MDCO
4
DELISTED
Medicines Co
MDCO
| $87.5M | 5.31% |
2,657,486
-151,468
| -5% | -$4.73M |
|
5
Post Holdings
POST
$4.15B
| $85.8M | 5.21% |
1,731,238
+206,575
| +14% | +$10.4M |
|
|
6
Nektar Therapeutics
NKTR
$2.38B
| $71M | 4.31% |
44,566
-46,579
| -51% | -$60M |
|
|
7
Zimmer Biomet
ZBH
$18.1B
| $70.1M | 4.25% |
661,932
+565,184
| +584% | +$65.6M |
|
8
Humana
HUM
$44.1B
| $68.3M | 4.15% |
254,246
-50,178
| -16% | -$13.6M |
|
9
DexCom
DXCM
$32.1B
| $66.6M | 4.04% |
3,590,480
+187,380
| +6% | +$2.77M |
|
10
Alnylam Pharmaceuticals
ALNY
$27.1B
| $65.5M | 3.97% |
549,632
+49,413
| +10% | +$6.37M |
|
11
Caesars Entertainment
CZR
$6.06B
| $61.2M | 3.71% |
1,855,250
-632,777
| -25% | -$21.2M |
|
12
Morgan Stanley
MS
$332B
| $58.1M | 3.52% |
1,076,809
-133,550
| -11% | -$7.39M |
|
13
MGM Resorts International
MGM
$11.4B
| $53.3M | 3.24% |
1,523,332
| – | – |
|
14
Incyte
INCY
$24.4B
| $51.8M | 3.14% |
622,152
| – | – |
|
|
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
| $50.2M | 3.05% |
2,531,245
+509,266
| +25% | +$10.9M |
|
|
WCG
16
DELISTED
Wellcare Health Plans, Inc.
WCG
| $48.5M | 2.94% |
250,339
+20,180
| +9% | +$4.04M |
|
17
Charter Communications
CHTR
$17.4B
| $43.7M | 2.65% |
140,460
+24,351
| +21% | +$8.56M |
|
18
Armstrong World Industries
AWI
$7.32B
| $43.3M | 2.63% |
769,622
-104,859
| -12% | -$6.36M |
|
19
Viasat
VSAT
$10.6B
| $37.5M | 2.28% |
570,979
+91,623
| +19% | +$6.68M |
|
|
20
Heron Therapeutics
HRTX
$95.4M
| $35.3M | 2.14% |
+1,277,560
| New | +$29M |
|
|
SGI
21
Somnigroup International
SGI
$14B
| $34.2M | 2.07% |
3,017,032
| – | – |
|
22
TG Therapeutics
TGTX
$8.01B
| $33.7M | 2.04% |
2,373,920
-2,017,714
| -46% | -$25.8M |
|
23
Liberty Broadband Class A
LBRDA
$4.9B
| $33.1M | 2.01% |
390,292
| – | – |
|
|
MSGN
24
DELISTED
MSG Networks Inc.
MSGN
| $30.4M | 1.85% |
+1,346,056
| New | +$31.7M |
|
25
Rocket Pharmaceuticals
RCKT
$337M
| $29.6M | 1.8% |
+1,578,569
| New | +$25.7M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q1 2018 Portfolio in Review
As of Q1 2018, Bridger Management held 41 positions worth $1.65B, up 8.8% from $1.52B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Bridger Management's Q1 2018 filing shows 8 new, 10 increased, 10 reduced and 4 closed positions. Its largest new stake was ScottsMiracle-Gro: 343,274 shares worth $29.4M. The largest sale was Nektar Therapeutics, an estimated $60M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Technology.
- Bridger Management's largest Q1 2018 buy was ScottsMiracle-Gro: 343,274 shares worth $29.4M.
- Bridger Management added most to Zimmer Biomet in Q1 2018, an estimated $65.6M increase.
- Bridger Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $60M.
- Bridger Management fully exited DaVita in Q1 2018, selling an estimated $52.3M.
- Bridger Management's ten largest holdings make up 49% of its $1.65B portfolio in Q1 2018.
- Bridger Management opened 8 new positions and closed 4 in Q1 2018.
- Bridger Management's portfolio value rose 8.8% quarter-over-quarter to $1.65B.
Based on Bridger Management's 13F filing for Q1 2018, filed 15 May 2018.